An evidence development process for newborn screening

Genetics in Medicine

Volumn 12, Issue 3, 2010, Pages 131-134

  Perrin, James M ^a   Knapp, Alixandra A ^a   Browning, Marsha F ^a   Comeau, Anne Marie ^a   Green, Nancy S ^a   Lipstein, Ellen A ^a   Metterville, Danielle R ^a   Prosser, Lisa ^a   Queally, Denise ^a   Kemper, Alex R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVIDENCE BASED MEDICINE; EXPERT WITNESS; GENETICS; HEALTH CARE PLANNING; HUMAN; NEWBORN; NEWBORN SCREENING; PATIENT ADVOCACY; RARE DISEASE; REVIEW; UNITED STATES;

EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HEALTH PLAN IMPLEMENTATION; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PATIENT ADVOCACY; RARE DISEASES; UNITED STATES;

EID: 79952277283     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181d28eb1     Document Type: Review

References (17)

1. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR, editors. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8(suppl 1):1S-252S.
2. Moyer VA, Calonge N, Teutsch SM, Botkin JR. Expanding newborn screening: process, policy, and priorities. Hastings Cent Rep 2008;38:32-39.
3. Howell RR. We need expanded newborn screening. Pediatrics 2006;117:1800-1805.
4. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics 2006;117:1793-1799.
5. Lloyd-Puryear MA, Tonniges T, Van Dyck PC, et al. American Academy of Pediatrics Newborn Screening Task Force Recommendations: how far have we come? Pediatrics 2006;117:S194-S211.
6. Green NS, Rinaldo P, Brower A, et al; Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Committee report: advancing the current recommended panel of conditions for newborn screening. Genet Med 2007;9:792-796.
7. Available at: http://www.cdc.gov/genomics/gtesting/EGAPP/index.htm. Accessed January 9, 2009.
8. Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001;20:21-35.
9. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E; U.S. Preventive Services Task Force. Current processes of the US Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med 2007;147:117-122.
10. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-930.
11. See Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children, minutes of meeting 10, “Process for nominating and evaluating conditions for inclusion on the uniform newborn screening panel.” Available at: http://www.hrsa.gov/heritabledisorderscommittee/meetings/2007may/minutes0507.htmc. Accessed August 1, 2009.
12. Rinaldo P, Zafari S, Tortorelli S, Matern D. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Ment Retard Dev Disabil Res Rev 2006;12:255-261.
13. Pass K, Green N, Lorey F, Sherwin J, Comeau AM. Pilot programs in newborn screening. Ment Retard Dev Disabil Res Rev 2006;12:4:293- 300.
14. NHS Center for Reviews and Dissemination March 2001. Accessed October 17, 2008.
15. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 2004;8:12.
16. Pollitt RJ, Green A, McCabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:i-iv, 1-202.
17. See Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children, Committee Reports. Available at: http://www.hrsa.gov/heritabledisorderscommittee/reports/, listed as KrabbeEvidenceReviewFinalDraft.pdf, evidencereviewSCID/default.htm, evidenceReviewPompeOct2008.htm. Accessed October 1, 2009.